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Background
Clinical trials in patients with advanced bladder cancer
have reported response rates of up to approximately 30%
and 60% with single-agent and multi-agent regimens,
respectively, and minimal improvements in survival over
best supportive care. Guidance on second-line treatment
options is unclear and no global standard exists. Nivolu-
mab, a fully human IgG4 programmed death-1 (PD-1)
immune checkpoint inhibitor antibody, has clinical activity
in multiple tumor types. Safety and activity will be evalu-
ated in a Phase I/II, open-label study of nivolumab alone
or in combination with ipilimumab in patients with
advanced or metastatic solid tumors, including bladder
cancer (NCT01928394). In a separate study and the focus
of this abstract (NCT02387996), we will estimate the effect
of nivolumab on tumor size and other safety and efficacy
parameters in patients with unresectable or metastatic
urothelial cancer progressing or recurring following
platinum-based chemotherapy.
Methods
This multinational study for advanced urothelial cancer
patients, which started in March 2015, is expected to
enroll as many as 250 patients and will be completed in
October 2017. Eligible patients have metastatic or surgi-
cally unresectable urothelial carcinoma with measurable
disease by imaging; disease progression or recurrence with
≥1 prior platinum-based regimen; and no liver metastases
if >2 prior lines of chemotherapy were administered. Addi-
tionally, patients who had cystectomy for localized urothe-
lial cancer along with disease recurrence or progression
within 12 months of neo-adjuvant or adjuvant platinum-
based treatment are eligible. Patients with active CNS
metastases are excluded. Nivolumab monotherapy will be
administered every 2 weeks until disease progression or
unacceptable toxicity. The primary endpoint is objective
response rate, and secondary endpoints include progres-
sion-free survival and overall survival. Further sub-analyses
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